The sky is not falling was the message in September 2017. Our message was that the overall market did not show excessive valuations, which generally is a precursor to stock market corrections. However, our market outlook dimmed due to recent ‘risk-on’ rally, where most of the year’s return was delivered... Show More
The degradation of addiction is only matched by the willing acceptance by the community of drugs of addiction the worst offenders being opioids which are regularly prescribed for chronic pain and which often lead on to death. Show More
Pharmaceutical group, Mayne Pharma (MYX) has posted a better than expected 278% lift in half year profit to $72.7m. The more than doubling of its revenue and near quadrupling of its net profit was driven by the acquisition of a portfolio of generic US drugs in August 2016, together with... Show More
Michael Glennon talks about Mayne Pharma Limited Show More
Pharmaceutical company, Mayne Pharma Group (MYX), reported a near quadrupling in Net Profit After Tax (NPAT) for the first half-year of 2016 to $19.2 million which was in line with consensus estimates For more Reporting Season coverage, please visit https://www.commsec.com.au/reportingseason Show More
Our Healhcare Analyst John Hester discusses the outlook and provides his top picks for 2016. Watch the video here: &feature=youtu.be Show More
What insights are listed company executives providing on the state of the Australian economy? According to Simon Conn who runs the small cap fund at Investors Mutual the message coming from both listed companies and those looking to IPO is the same. Australia is entrenched in a low/slow growth environment.... Show More